A
Anja De Weggheleire
Researcher at Institute of Tropical Medicine Antwerp
Publications - 29
Citations - 476
Anja De Weggheleire is an academic researcher from Institute of Tropical Medicine Antwerp. The author has contributed to research in topics: Hepatitis C & Ebola virus. The author has an hindex of 9, co-authored 29 publications receiving 372 citations.
Papers
More filters
Journal ArticleDOI
Prozone in malaria rapid diagnostics tests: how many cases are missed?
Philippe Gillet,Annelies Scheirlinck,Jocelijn Stokx,Anja De Weggheleire,Helder S. Chauque,Oreana D. J. V. Canhanga,Benvindo T. Tadeu,Carla D. D. Mosse,Armindo Tiago,Samuel Mabunda,Cathrien A. Bruggeman,Emmanuel Bottieau,Jan Jacobs +12 more
TL;DR: Prozone occurs at different frequency and intensity in HRP-2 R DTs and may decrease diagnostic accuracy in the most affected RDTs.
Journal ArticleDOI
Seroprevalence of transfusion-transmissible infections and evaluation of the pre-donation screening performance at the Provincial Hospital of Tete, Mozambique
Jocelijn Stokx,Philippe Gillet,Anja De Weggheleire,Esther C. Casas,Rosa Maendaenda,Adelino J Beulane,Ilhes V Jani,Solon Kidane,Carla D. D. Mosse,Jan Jacobs,Emmanuel Bottieau +10 more
TL;DR: The seroprevalence of TTIs after questionnaire screening is high in Tete, Mozambique, but HCV infection does not appear as a major issue, and a contextualized questionnaire and consistent use of quality-assured assays would considerably improve the current screening procedure for blood donation.
Journal ArticleDOI
Hepatitis B and C co-infection among HIV-infected adults while on antiretroviral treatment: long-term survival, CD4 cell count recovery and antiretroviral toxicity in Cambodia.
Johan van Griensven,Lay Phirum,Kimcheng Choun,Sopheak Thai,Anja De Weggheleire,Lutgarde Lynen +5 more
TL;DR: HBV and HCV co- Infection was associated with worse ART outcomes and the effect of early ART initiation and providing effective treatment for hepatitis co-infection should be explored.
Journal ArticleDOI
Treatment of acute hepatitis C genotypes 1 and 4 with 8 weeks of grazoprevir plus elbasvir (DAHHS2): an open-label, multicentre, single-arm, phase 3b trial
Anne Boerekamps,Anja De Weggheleire,Guido E.L. van den Berk,F. N. Lauw,Mark A. A. Claassen,Dirk Posthouwer,Wouter F W Bierman,Sebastiaan J. Hullegie,Stephanie Popping,David A C M van de Vijver,Anthonius S. M. Dofferhoff,Gert Jan Kootstra,Eliane M. S. Leyten,Jan G den Hollander,Marjo E. E. van Kasteren,Robert Soetekouw,Heidi S. M. Ammerlaan,Janke Schinkel,Eric Florence,Joop E. Arends,Bart J. A. Rijnders +20 more
TL;DR: 8 weeks of grazoprevir plus elbasvir was highly effective for the treatment of acute HCV genotype 1 or 4 infection and whether treatment can be shortened during the acute phase of HCV infection is investigated.
Journal ArticleDOI
Time for "test and treat" in prevention of mother-to-child transmission programs in low- and middle-income countries.
TL;DR: In these settings, universal ART initiation among HIV-positive pregnant women, irrespective of CD4 cell count or clinical staging, is a potentially superior strategy for the prevention of vertical transmission and the improvement of mothers' health.